A Part of the University of Maryland Medical Center

Connect with UMGCC
Facebook Twitter YouTube Blog iPhone
Email PageEmail page Print PagePrint page

Researcher Information

Angela Hartley Brodie, Ph.D.
Professor of Pharmacology

Pharmacology & Experimental Therapeutics

UMGCC Research Program:
Hormone Responsive Cancers Program

College Degree: B.Sc. (Hons) Sheffield University, UK
Post Doctoral Degree: Ph.D. Manchester University, UK
Fellowship: NIH Fellowship in Steroid Biochemistry, Clark University, MA

Contact Information:

Mailing Address: Room 580G, Health Sciences Facility 1
Dept. of Pharmacology
University of Maryland School of Medicine
685 W. Baltimore St.
Baltimore, MD 21201
Email: abrodie@umaryland.edu
Phone: 410-706-3137
Fax: 410-706-0032

Research Interests:
Breast cancer treatment, development of aromatase inhibitors. Formestane (4-hydroxyandrostenedione) was the first selective aromatase inhibitor to be used clinically and was the only new drug specifically designed for the treatment of breast cancer in 10 years. Formestane was released for world- wide use in 1994. Other research areas include development of androgen synthesis inhibitors as new treatments for prostate cancer; steroid biochemistry and endocrinology of breast and prostate cancer and other estrogen mediated diseases; reproductive endocrinology

For More Information:
Dr. Brodie is the 2005 recipient of the Kettering Prize from the General Motors Cancer Research Foundation (GMCRF)and was awarded the 2006 Dorothy P. Landon-AACR Prize for Translational Cancer Research for her groundbreaking work in developing aromatase inhibitors, a new class of breast cancer drugs. Learn more.

Brodie AMH, Schwarzel WC, Shaikh AA, Brodie HJ: The Effect of an Aromatase Inhibitor, 4-Hydroxy-4-Androstene-3,17-Dione, on Estrogen Dependent Processes in Reproduction and Breast Cancer. Endocrinology, 100:1684-1695, 1977.

Coombes CR, Goss P, Dowsett M, Gazet JC, Brodie A: 4-Hydroxyandostenedione in Treatment of Postmenopausal Patients with Advanced Breast Cancer. Lancet, 2:1237-1239, 1984

Goss PE, Coombes RL, Powles TJ, Dowsett M, Brodie AMH: Treatment of Advanced Postmenopausal Breast Cancer with Aromatase Inhibitor, 4-Hydroxyandrostenedione-Phase 2 Report. Cancer Res, 46:4823-4826, 1986.

Njar VCO, Brodie AMH: Inhibitors of 17รก-Hydroxylase/C17,20-Lyase (CYP17): Potential Agents for the Treatment of Prostate Cancer. Current Pharm Design, 5:163-180, 1999

Nnane IP, Kato K, Liu Y, Long BJ, Lu Q, Wang X, Ling YZ, Brodie AMH: Inhibition of Androgen Synthesis in Human Testicular and Prostatic Microsomes and in Male Rats by Novel Steroidal Compounds. Endocrinology, 140:2891-2897,1999

Long B, Grigoryev D, Nnane I, Liu Y, Ling YZ, Brodie A: Antiandrogen Effects of Novel Inhibitors of Androgen Synthesis Inhibitors on Hormone-dependent Prostate Cancer. Cancer Res, 60:6630-6640, 2000.

Brodie A: Aromatase Inhibitors and the Application to the Treatment of Breast Cancer. In: Breast Cancer: Prognosis, Treatment and Prevention, ed. Jorge Pasqualini, Chapter 8, pp. 251-270, 2002, Marcel Dekker, NY.

Long BJ, Jelovac D, Handratta V, Thiantanawat A, MacPherson N, Ragaz J, Brodie AM: Therapeutic Strategies Using the Aromatase Inhibitor Letrozole and Tamoxifen in a Breast Cancer Model. JNCI 96:456-465,2004.